Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Lijie Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5919-3773; OpenAlex author ID A5002148103. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2022: 3 papers · 2023: 3 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 8

  1. ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41421-026-00882-9↗
  2. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  3. Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal… First author DOI 10.1007/s00262-023-03438-y↗
  4. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.1038/s41467-023-40314-w↗
  5. LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2411868/v1↗
  6. Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy a… First author DOI 10.1002/ctm2.1126↗
  7. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-1516835/v1↗
  8. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2065916/v1↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lingxi Jiang · 6 shared papers, 2022–2024 · strength 0.84
  2. Hao Chen · 5 shared papers, 2022–2026 · strength 0.83
  3. Yizhi Cao · 5 shared papers, 2022–2024 · strength 0.69
  4. Chenghong Peng · 5 shared papers, 2022–2024 · strength 0.69
  5. Youwei Zhu · 4 shared papers, 2022–2024 · strength 0.58
  6. Meilin Xue · 4 shared papers, 2022–2024 · strength 0.58
  7. Yongsheng Jiang · 4 shared papers, 2022–2024 · strength 0.56
  8. Hao Chen · 3 shared papers, 2023–2024 · strength 0.44
  9. Jiaxin Luo · 3 shared papers, 2022–2024 · strength 0.43
  10. Cheng Xiong · 3 shared papers, 2022–2023 · strength 0.43
  11. Jiewei Lin · 3 shared papers, 2022–2023 · strength 0.41
  12. Zengyu Feng · 3 shared papers, 2022–2023 · strength 0.41
  13. Kexian Li · 3 shared papers, 2022–2023 · strength 0.41
  14. Kai Qin · 3 shared papers, 2022–2023 · strength 0.41
  15. Yongsheng Jiang · 2 shared papers, 2022–2023 · strength 0.29
  16. Baiyong Shen · 2 shared papers, 2022–2023 · strength 0.29
  17. Baiyong Shen · 2 shared papers, 2023–2024 · strength 0.29
  18. Dillon Matthew Voss · 1 shared paper, 2026 · strength 0.28
  19. Adrian R. Krainer · 1 shared paper, 2026 · strength 0.28
  20. Jiancheng Wang · 2 shared papers, 2022–2023 · strength 0.28
  21. Jiän Zhang · 1 shared paper, 2023 · strength 0.16
  22. Minwei Yang · 1 shared paper, 2023 · strength 0.16
  23. Jiejie Qin · 1 shared paper, 2024 · strength 0.15
  24. Xiaomei Tang · 1 shared paper, 2024 · strength 0.15
  25. Shuyu Zhai · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.